首頁>最新消息>返回列表
媒體報導
07.Oct.2022

瀚源生醫與伊利諾大學香檳分校Bashir教授的實驗室合作

 

 The very first of its kind commercial semiconductor field-effect transistor (FET) biosensor platform donated from Helios Bioelectronics Inc to collaborators at the Laboratory of Integrated Biomedical Micro/Nanotechnology & Applications, University of Illinois at Urbana-Champaign (LIBNA@UIUC). From left: Enrique Valera, Justin Liang, Yi-Shao Liu, Rashid Bashir, Katherine Koprowski, Janice Baek, Jongwon Lim.

 

 

Paving the way for your ideal Biomarkers

The BioFET (field-effect transistor) platform can detect any target with a net charge including nucleic acids (e.g. miRNA), proteins, bacteria, cells, etc. The BioFET chips are customizable through immobilization of target-specific probes onto the chip surface. Minimal sample preparation is required and no labeling is necessary for target detection. Over one million biosensors are contained on a single BioFET chip the size of a fingertip. This allows for detection of multiple targets on a single BioFET chip with significant statistical power.

 

 

POCT Empowered with Portable-sized BioFET Device

Datagenerated from BioFET chips is transmitted via cloud computing for artificialintelligence (AI) analysis. Simple data management coupled with the portabilityof the BioFET device make it possible for personalized, decentralized moleculardiagnostics to be readily available for rapidly growing point of care testing (POCT)markets.

 

       

       Fig.1. Discover the science behind the BioFET platform and its advantages in less than 2 min!

 

 

A strategic partnership and collaboration between Helios Bioelectronics Inc. and the Laboratory of Integrated Biomedical Micro/Nanotechnology & Applications (LIBNA), University of Illinois at Urbana-Champaign (UIUC)